Publication: Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
1
Issued Date
2015-01-01
Resource Type
ISSN
15537374
15537366
15537366
Other identifier(s)
2-s2.0-84940771125
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS Pathogens. Vol.11, No.8 (2015)
Suggested Citation
Sampa Santra, Georgia D. Tomaras, Ranjit Warrier, Nathan I. Nicely, Hua Xin Liao, Justin Pollara, Pinghuang Liu, S. Munir Alam, Ruijun Zhang, Sarah L. Cocklin, Xiaoying Shen, Ryan Duffy, Shi Mao Xia, Robert J. Schutte, Charles W. Pemble IV, S. Moses Dennison, Hui Li, Andrew Chao, Kora Vidnovic, Abbey Evans, Katja Klein, Amit Kumar, James Robinson, Gary Landucci, Donald N. Forthal, David C. Montefiori, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Kelly A. Soderberg, Elena E. Giorgi, Lily Blair, Bette T. Korber, Christiane Moog, Robin J. Shattock, Norman L. Letvin, Joern E. Schmitz, M. A. Moody, Feng Gao, Guido Ferrari, George M. Shaw, Barton F. Haynes Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens. Vol.11, No.8 (2015). doi:10.1371/journal.ppat.1005042 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/35652
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Author(s)
Sampa Santra
Georgia D. Tomaras
Ranjit Warrier
Nathan I. Nicely
Hua Xin Liao
Justin Pollara
Pinghuang Liu
S. Munir Alam
Ruijun Zhang
Sarah L. Cocklin
Xiaoying Shen
Ryan Duffy
Shi Mao Xia
Robert J. Schutte
Charles W. Pemble IV
S. Moses Dennison
Hui Li
Andrew Chao
Kora Vidnovic
Abbey Evans
Katja Klein
Amit Kumar
James Robinson
Gary Landucci
Donald N. Forthal
David C. Montefiori
Jaranit Kaewkungwal
Sorachai Nitayaphan
Punnee Pitisuttithum
Supachai Rerks-Ngarm
Merlin L. Robb
Nelson L. Michael
Jerome H. Kim
Kelly A. Soderberg
Elena E. Giorgi
Lily Blair
Bette T. Korber
Christiane Moog
Robin J. Shattock
Norman L. Letvin
Joern E. Schmitz
M. A. Moody
Feng Gao
Guido Ferrari
George M. Shaw
Barton F. Haynes
Georgia D. Tomaras
Ranjit Warrier
Nathan I. Nicely
Hua Xin Liao
Justin Pollara
Pinghuang Liu
S. Munir Alam
Ruijun Zhang
Sarah L. Cocklin
Xiaoying Shen
Ryan Duffy
Shi Mao Xia
Robert J. Schutte
Charles W. Pemble IV
S. Moses Dennison
Hui Li
Andrew Chao
Kora Vidnovic
Abbey Evans
Katja Klein
Amit Kumar
James Robinson
Gary Landucci
Donald N. Forthal
David C. Montefiori
Jaranit Kaewkungwal
Sorachai Nitayaphan
Punnee Pitisuttithum
Supachai Rerks-Ngarm
Merlin L. Robb
Nelson L. Michael
Jerome H. Kim
Kelly A. Soderberg
Elena E. Giorgi
Lily Blair
Bette T. Korber
Christiane Moog
Robin J. Shattock
Norman L. Letvin
Joern E. Schmitz
M. A. Moody
Feng Gao
Guido Ferrari
George M. Shaw
Barton F. Haynes
Other Contributor(s)
Harvard Medical School
Duke University
University of Pennsylvania
Imperial College London
Tulane University School of Medicine
University of California, Irvine
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Walter Reed Army Institute of Research
Los Alamos National Laboratory
Inserm
Duke University
University of Pennsylvania
Imperial College London
Tulane University School of Medicine
University of California, Irvine
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Walter Reed Army Institute of Research
Los Alamos National Laboratory
Inserm
Abstract
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across mucosal epithelium to infect CD4<sup>+</sup> T cells. Although broadly neutralizing antibodies (bnAbs) are the type of HIV-1 antibodies that are most likely protective, they are not induced with current vaccine candidates. In contrast, antibodies that do not neutralize primary HIV-1 strains in the TZM-bl infection assay are readily induced by current vaccine candidates and have also been implicated as secondary correlates of decreased HIV-1 risk in the RV144 vaccine efficacy trial. Here, we have studied the capacity of anti-Env monoclonal antibodies (mAbs) against either the immunodominant region of gp41 (7B2 IgG1), the first constant region of gp120 (A32 IgG1), or the third variable loop (V3) of gp120 (CH22 IgG1) to modulate in vivo rectal mucosal transmission of a high-dose simian-human immunodeficiency virus (SHIV-BaL) in rhesus macaques. 7B2 IgG1 or A32 IgG1, each containing mutations to enhance Fc function, was administered passively to rhesus macaques but afforded no protection against productive clinical infection while the positive control antibody CH22 IgG1 prevented infection in 4 of 6 animals. Enumeration of transmitted/founder (T/F) viruses revealed that passive infusion of each of the three antibodies significantly reduced the number of T/F genomes. Thus, some antibodies that bind HIV-1 Env but fail to neutralize virus in traditional neutralization assays may limit the number of T/F viruses involved in transmission without leading to enhancement of viral infection. For one of these mAbs, gp41 mAb 7B2, we provide the first co-crystal structure in complex with a common cyclical loop motif demonstrated to be critical for infection by other retroviruses.